Gambro, Baxter to research seven-day platelet study

By Elaine Rigoli

Tampa, Fla., May 17 - Gambro BCT, Inc. and Baxter Healthcare Corp. will collaborate on a post-market surveillance study, which enables Baxter to join Gambro's Food and Drug Administration-approved Passport study to facilitate seven-day platelet implementation.

Prior to Gambro and Baxter receiving FDA clearance, platelets had to be transfused within five days of collection due to bacterial concerns. New testing technologies have dramatically reduced these risks allowing for extended storage times, according to a news release.

By safely extending the shelf life by two days, blood centers can reduce platelet supply shortages that often occur, the release said.

Platelets are transfused to people who are undergoing chemotherapy, cardiothoracic surgery and for the treatment of other critical medical conditions.

Located in Lakewood, Colo., Gambro is a wholly owned subsidiary of Gambro AB, an international medical technology and health care company.

Baxter is a medical products and services company located in Deerfield, Ill.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.